Category: Pα+ - Page 4 - Psychedelic Alpha

Read more about the article Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Post published:January 10, 2025
Post category:Analysis News Pα+

Read more about the article From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics

From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics

Post published:January 7, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24, with MDMA-AT the Key Topic

Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24, with MDMA-AT the Key Topic

Post published:December 31, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Post published:December 20, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians

Pα+ Psychedelic Bulletin #183: UW Madison’s Psychedelic Symposium; MindMed Doses First Phase 3 Patient; Beckley’s IV Psilocin Readout; Psilocybin for COVID Clinicians

Post published:December 18, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding

Post published:December 10, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field

Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field

Post published:December 5, 2024
Post category:Interviews Pα+

Read more about the article Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

Psychedelic Drug Development Under Trump 2.0: Health Nominees Signal Uncertain Future

Post published:November 30, 2024
Post category:Analysis News Pα+

Read more about the article Q3’24 Survey: What are Psychedelics Investors Concerned About?

Q3’24 Survey: What are Psychedelics Investors Concerned About?

Post published:November 27, 2024
Post category:Analysis News Pα+

Read more about the article Q3’24 Survey: What are Psychedelics Investors Excited About?

Q3’24 Survey: What are Psychedelics Investors Excited About?

Post published:November 25, 2024
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.